Australian Government

Department of Health
Therapeutic Goods Administration

Therapeutic Goods Act 1989
Approval under section 42DF for use of restricted representations by Bayer Australia Limited

I, Rowena Love, Delegate of the Secretary to the Department of Health, on receipt of an application from Bayer Australia Limited, have approved under section 42DF of the *Therapeutic Goods Act 1989* (the **Act**) the use of the below stated restricted representations in advertisements directed to consumers, for the following medicines:

ALEVE 24 HOUR Naproxen sodium 660mg modified release tablet (AUST R 263421)

i. For the temporary relief of persistent pain and inflammation likely to last for more than 12 hours associated with arthritis and/or osteoarthritis.

ii. Reduces stiffness in muscles and joints associated with osteoarthritis.

ALEVE 24 HOUR Naproxen sodium 660mg modified release tablet (AUST R 263421)

i. For the temporary relief of pain and inflammation associated with arthritis and/or osteoarthritis.

ii. Temporary relief of stiffness associated with osteoarthritis.

Dated this 23rd day of October 2020

Signed electronically

Rowena Love
Delegate of the Secretary to the Department of Health
Advertising Education and Assurance Section
Regulatory Compliance Branch